


## Ac-VLPE-FMK

<b>Cat. No.:</b>	HY-153614		
<b>CAS No.:</b>	2679825-27-3		
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>41</sub> FN <sub>4</sub> O <sub>7</sub>		
<b>Molecular Weight:</b>	528.61		
<b>Target:</b>	Cathepsin		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	Ac-VLPE-FMK, a tetrapeptidyl mono-fluoromethyl ketone (m-FMK), is a Cat-B and Cat-L inhibitor. Ac-VLPE-FMK can be used for the research of cancer aggressiveness <sup>[1][2]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	Cathepsin B	cathepsin L
<b>In Vitro</b>	<p>Ac-VLPE-FMK (2 μM) significantly affects the cleavage of probe Ac-PLVQ-AMC by human recombinant CtsB and L<sup>[1]</sup>.</p> <p>Ac-VLPE-FMK (30 min) inhibits the generation of the fluorescence derived from the cleavage of the substrate Ac-PLVQ-AMC in 769-p and A498 cells<sup>[1]</sup>.</p> <p>Ac-VLPE-FMK (2.5-250 μM; 24-72 h) does not affect renal cancer cell viability, but influences cell migration rate, cellular adhesion, colony formation, and markers expression in renal cancer cells<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	

### REFERENCES

- [1]. Rudzińska M, et, al. Cysteine Cathepsins Inhibition Affects Their Expression and Human Renal Cancer Cell Phenotype. *Cancers (Basel)*. 2020 May 21;12(5):1310.
- [2]. Citarella A, et, al. Peptidyl Fluoromethyl Ketones and Their Applications in Medicinal Chemistry. *Molecules*. 2020 Sep 3;25(17):4031.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA